Press release
Achondroplasia Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Ascendis, BioMarin Pharmaceutical, Pfizer, PhaseBio Pharmaceuticals, ProLynx Inc, QED Therapeutics (BridgeBio), Ribomic, Sanofi
"Achondroplasia Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Achondroplasia Therapeutics Market.
The report provides a detailed description of the Achondroplasia drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Achondroplasia Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/achondroplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Achondroplasia Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Achondroplasia therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Achondroplasia treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Achondroplasia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Achondroplasia treatment market.
Learn More about the Clinical and Commercial Development Activities in the Achondroplasia Therapeutics Domain:
https://www.delveinsight.com/report-store/achondroplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Achondroplasia Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Achondroplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Subcutaneous etc.
Molecule Type
Products have been categorized under various Molecule types such as
• Natriuretic peptides
• Recombinant fusion proteins
• Small molecule
Request for Sample PDF to Understand More About the Achondroplasia Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/achondroplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Achondroplasia Therapeutics Assessment
The current treatment landscape includes medications such as growth hormone therapy, surgery, and supportive therapy for achondroplasia. The first drug to be approved for treating achondroplasia is VOXZOGO (Vosoritide) by BioMarin Pharmaceuticals. The European Commission granted marketing authorization to VOXZOGO as a once-daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height, in August 2021. In November 2021, US FDA approved VOXZOGO, under accelerated approval pathway, and Rare Pediatric Disease Priority Review Voucher, fastening the approval timeline. Marketing authorization reviews are in process in Japan, Brazil, and Australia, with potential approvals in these countries in 2022.
Several major pharma and biotech giants are developing therapies for Achondroplasia. Currently, BioMarin Pharmaceutical is leading the therapeutics market with its Achondroplasia drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Achondroplasia Therapeutics Market Include:
• Ascendis Pharma
• BioMarin Pharmaceutical
• Pfizer
• PhaseBio Pharmaceuticals
• ProLynx Inc
• QED Therapeutics (BridgeBio)
• Ribomic
• Sanofi
And Many Others
Achondroplasia Emerging and Marketed Drugs Covered in the Report Include:
• BMN-111: BioMarin Pharmaceutical
• CNP-ELP: PhaseBio
• Infigratinib: QED Therapeutics (BridgeBio)
• PLX138: ProLynx Inc
• Recifercept (TA 46): Pfizer
• SAR442501: Sanofi
• TransCon CNP: Ascendis Pharma
And Many More
Get an in-depth Assessment of the Emerging Therapies and Achondroplasia Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/achondroplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Achondroplasia Current Treatment Patterns
4. Achondroplasia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Achondroplasia Late-Stage Products (Phase-III)
7. Achondroplasia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Achondroplasia Discontinued Products
13. Achondroplasia Product Profiles
14. Achondroplasia Companies
15. Achondroplasia Drugs
16. Dormant and Discontinued Products
17. Achondroplasia Unmet Needs
18. Achondroplasia Future Perspectives
19. Achondroplasia Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/achondroplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Anaplastic Astrocytoma Market
https://www.delveinsight.com/report-store/anaplastic-astrocytoma-market
Singapore Healthcare Outlook
https://www.delveinsight.com/report-store/singapore-healthcare-outlook-report
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market
https://www.delveinsight.com/report-store/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market
Chronic Idiopathic Constipation Market
https://www.delveinsight.com/report-store/chronic-idiopathic-constipation-market
Hay Fever Conjunctivitis Market
https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market
Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market
Cerebral Infarction Market
https://www.delveinsight.com/report-store/cerebral-infarction-market
CART-related Neurotoxicity (NT) Market
https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market
Hernia Repair Devices Market
https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bronchial Hyperreactivity Market
https://www.delveinsight.com/report-store/bronchial-hyperreactivity-market
Chronic Focal Epilepsy Market
https://www.delveinsight.com/report-store/chronic-focal-epilepsy-market
Dental Lasers Market
https://www.delveinsight.com/report-store/dental-lasers-market
Down Syndrome Market
https://www.delveinsight.com/report-store/down-syndrome-market
Extracorporeal Circulation System Market
https://www.delveinsight.com/report-store/extracorporeal-circulation-system-market
Failed Back Surgery Syndrome Market
https://www.delveinsight.com/report-store/failed-back-surgery-syndrome-market
Germ Cell Tumor Market
https://www.delveinsight.com/report-store/germ-cell-tumor-market
Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market
India Healthcare Outlook
https://www.delveinsight.com/report-store/india-healthcare-outlook-report
Insulin Glargine Biosimilar
https://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight
Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market
Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market
Mucopolysaccharidosis I Market
https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market
Nasolabial Fold Market
https://www.delveinsight.com/report-store/nasolabial-fold-market
Neuroleptic Malignant Syndrome Market
https://www.delveinsight.com/report-store/neuroleptic-malignant-syndrome-market
Pachyonychia Congenita Market
https://www.delveinsight.com/report-store/pachyonychia-congenita-market
Point of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
Reactive Airway Disease Market
https://www.delveinsight.com/report-store/reactive-airway-disease-market
Seborrhea Market
https://www.delveinsight.com/report-store/seborrhea-market
Substance (Drug) Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market
Synchronous Endometrial and Ovarian Cancer (SEOC) Market
https://www.delveinsight.com/report-store/synchronous-endometrial-and-ovarian-cancer-seoc-market
Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
Urinary Tract Infection Devices Market
https://www.delveinsight.com/report-store/urinary-tract-infection-devices-market
Varicose Veins Market
https://www.delveinsight.com/report-store/varicose-veins-market
Vulvodynia Market
https://www.delveinsight.com/report-store/vulvodynia-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Achondroplasia Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Ascendis, BioMarin Pharmaceutical, Pfizer, PhaseBio Pharmaceuticals, ProLynx Inc, QED Therapeutics (BridgeBio), Ribomic, Sanofi here
News-ID: 3153853 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Achondroplasia
Achondroplasia Market Industry Trends and Forecast to 2029
This Achondroplasia Market report has been prepared by considering several fragments of the present and upcoming market scenario. The market insights gained through this market research analysis report facilitates more clear understanding of the market landscape, issues that may interrupt in the future, and ways to position definite brand excellently. It consists of most-detailed market segmentation, thorough analysis of major market players, trends in consumer and supply chain…
Achondroplasia Treatment Market An Professional Research Report 2023-2029 | Surv …
Achondroplasia is a disorder of bone growth that prevents the changing of cartilage (particularly in the long bones of the arms and legs) to bone. It is characterized by dwarfism, limited range of motion at the elbows, large head size (macrocephaly), small fingers, and normal intelligence. Achondroplasia (ACH) is a rare disease that causes short stature (adult height of approximately 130 cm for males and approximately 125 cm for females)…
Achondroplasia Treatment Market Size, Share, Industry, Forecast to 2030
The Achondroplasia Treatment Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Achondroplasia Treatment market. This report explores all the key factors affecting the growth of the global Achondroplasia Treatment market, including…
Achondroplasia Treatment Market to witness Great Growth in Forecast to 2030
The professional report on The Achondroplasia Treatment Market research provides valuable insights on business size, ongoing trends, drivers, potential risks, outcomes, and significant segments. Additionally, the Industry Report presents precise assumptions to forecast future market growth. Drawing from industry experts, the report's findings offer actionable measures that help readers develop effective strategies for the Achondroplasia Treatment market's future growth. Furthermore, the research provides a comprehensive view of present market needs…
Achondroplasia Market: Pipeline Review, H2 2022
HTF Market Intelligence released a new research report of 60 pages on title 'Achondroplasia - Pipeline Review, H2 2022' with detailed analysis, forecast and strategies. The market Study is segmented by key a region that is accelerating the marketization. The study is a perfect mix of qualitative and quantitative Market data collected and validated majorly through primary data and secondary sources. This section also provides the scope of different…
Achondroplasia Market Insight, Epidemiology and Market Forecast - 2027
Achondroplasia Market research report is the new statistical data source added by Infinity Business Insights.
Achondroplasia is a genetic disease characterised by dwarfism as its major symptom. The limbs and legs of people who have the disease are short, but the torso is usually average length. Males have an average adult height of 131 centimetres (4 ft 4 in) while girls have an average adult height of 123 centimetres (4…
